Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Protalix BioTherapeutics (PLX) over the last 6 years, with Q3 2025 value amounting to $52910.0.

  • Protalix BioTherapeutics' Gains from Sales and Divestitures changed N/A to $52910.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $52910.0, marking a year-over-year change of. This contributed to the annual value of $992313.0 for FY2024, which is 10285.81% up from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Gains from Sales and Divestitures stood at $52910.0.
  • Protalix BioTherapeutics' Gains from Sales and Divestitures' 5-year high stood at $992313.0 during Q4 2024, with a 5-year trough of $52910.0 in Q3 2025.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $489166.0 (2023), whereas its average is $525395.4.
  • In the last 5 years, Protalix BioTherapeutics' Gains from Sales and Divestitures surged by 45600.02% in 2022 and then tumbled by 4717.63% in 2023.
  • Protalix BioTherapeutics' Gains from Sales and Divestitures (Quarter) stood at $166553.0 in 2021, then surged by 456.0% to $926035.0 in 2022, then crashed by 47.18% to $489166.0 in 2023, then soared by 102.86% to $992313.0 in 2024, then crashed by 94.67% to $52910.0 in 2025.
  • Its Gains from Sales and Divestitures was $52910.0 in Q3 2025, compared to $992313.0 in Q4 2024 and $489166.0 in Q4 2023.